» Articles » PMID: 21593864

Progress and Challenges in Translating the Biology of Atherosclerosis

Overview
Journal Nature
Specialty Science
Date 2011 May 20
PMID 21593864
Citations 1508
Authors
Affiliations
Soon will be listed here.
Abstract

Atherosclerosis is a chronic disease of the arterial wall, and a leading cause of death and loss of productive life years worldwide. Research into the disease has led to many compelling hypotheses about the pathophysiology of atherosclerotic lesion formation and of complications such as myocardial infarction and stroke. Yet, despite these advances, we still lack definitive evidence to show that processes such as lipoprotein oxidation, inflammation and immunity have a crucial involvement in human atherosclerosis. Experimental atherosclerosis in animals furnishes an important research tool, but extrapolation to humans requires care. Understanding how to combine experimental and clinical science will provide further insight into atherosclerosis and could lead to new clinical applications.

Citing Articles

Causal relationship between drug target genes of LDL-cholesterol and coronary artery disease: drug target Mendelian randomization study.

Jee Y, Shin J, Ryu M, Song T Lipids Health Dis. 2025; 24(1):92.

PMID: 40082904 PMC: 11905656. DOI: 10.1186/s12944-025-02502-z.


An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis.

El Bounkari O, Zan C, Yang B, Ebert S, Wagner J, Bugar E Nat Commun. 2025; 16(1):2297.

PMID: 40055309 PMC: 11889166. DOI: 10.1038/s41467-025-57540-z.


Innovative Atherosclerosis Models: Advancing Pathophysiology and Translational Research.

Jiang H, Liao Y, Zhu M, Jiramonai L, Wu H, Zhong Y Research (Wash D C). 2025; 8:0617.

PMID: 40046514 PMC: 11881979. DOI: 10.34133/research.0617.


Motor protein KIF13B orchestrates hepatic metabolism to prevent metabolic dysfunction-associated fatty liver disease.

Miao G, Zhang W, Xu Y, Liu Y, Lai P, Guo J Mil Med Res. 2025; 12(1):11.

PMID: 40038775 PMC: 11877712. DOI: 10.1186/s40779-025-00594-3.


PRDM16 controls smooth muscle cell fate in atherosclerosis.

Tan J, Cheng L, Calhoun R, Weller A, Drareni K, Fong S bioRxiv. 2025; .

PMID: 40027729 PMC: 11870537. DOI: 10.1101/2025.02.19.639186.


References
1.
Kawakami A, Osaka M, Aikawa M, Uematsu S, Akira S, Libby P . Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res. 2008; 103(12):1402-9. PMC: 2994199. DOI: 10.1161/CIRCRESAHA.108.178426. View

2.
Caligiuri G, Nicoletti A, Poirier B, Hansson G . Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest. 2002; 109(6):745-53. PMC: 150903. DOI: 10.1172/JCI7272. View

3.
Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O . Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med. 2009; 206(10):2067-77. PMC: 2757872. DOI: 10.1084/jem.20090545. View

4.
Taleb S, Tedgui A, Mallat Z . Interleukin-17: friend or foe in atherosclerosis?. Curr Opin Lipidol. 2010; 21(5):404-8. DOI: 10.1097/MOL.0b013e32833dc7f9. View

5.
Gimbrone Jr M, Topper J, Nagel T, Anderson K, Garcia-Cardena G . Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci. 2000; 902:230-9; discussion 239-40. DOI: 10.1111/j.1749-6632.2000.tb06318.x. View